These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 18849360

  • 1. Ligand selectivity of D2 dopamine receptors is modulated by changes in local dynamics produced by sodium binding.
    Ericksen SS, Cummings DF, Weinstein H, Schetz JA.
    J Pharmacol Exp Ther; 2009 Jan; 328(1):40-54. PubMed ID: 18849360
    [Abstract] [Full Text] [Related]

  • 2. Certain 1,4-disubstituted aromatic piperidines and piperazines with extreme selectivity for the dopamine D4 receptor interact with a common receptor microdomain.
    Kortagere S, Gmeiner P, Weinstein H, Schetz JA.
    Mol Pharmacol; 2004 Dec; 66(6):1491-9. PubMed ID: 15448188
    [Abstract] [Full Text] [Related]

  • 3. Nonconserved residues in the second transmembrane-spanning domain of the D(4) dopamine receptor are molecular determinants of D(4)-selective pharmacology.
    Schetz JA, Benjamin PS, Sibley DR.
    Mol Pharmacol; 2000 Jan; 57(1):144-52. PubMed ID: 10617689
    [Abstract] [Full Text] [Related]

  • 4. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
    Grundt P, Carlson EE, Cao J, Bennett CJ, McElveen E, Taylor M, Luedtke RR, Newman AH.
    J Med Chem; 2005 Feb 10; 48(3):839-48. PubMed ID: 15689168
    [Abstract] [Full Text] [Related]

  • 5. Interactions of ligands with active and inactive conformations of the dopamine D2 receptor.
    Malmberg A, Mohell N, Backlund Höök B, Johansson AM, Hacksell U, Nordvall G.
    Eur J Pharmacol; 1998 Apr 10; 346(2-3):299-307. PubMed ID: 9652373
    [Abstract] [Full Text] [Related]

  • 6. Structural determinants of pharmacological specificity between D(1) and D(2) dopamine receptors.
    Lan H, Durand CJ, Teeter MM, Neve KA.
    Mol Pharmacol; 2006 Jan 10; 69(1):185-94. PubMed ID: 16236817
    [Abstract] [Full Text] [Related]

  • 7. Histidine 6.55 is a major determinant of ligand-biased signaling in dopamine D2L receptor.
    Tschammer N, Bollinger S, Kenakin T, Gmeiner P.
    Mol Pharmacol; 2011 Mar 10; 79(3):575-85. PubMed ID: 21163968
    [Abstract] [Full Text] [Related]

  • 8. The human D2 dopamine receptor synergizes with the A2A adenosine receptor to stimulate adenylyl cyclase in PC12 cells.
    Kudlacek O, Just H, Korkhov VM, Vartian N, Klinger M, Pankevych H, Yang Q, Nanoff C, Freissmuth M, Boehm S.
    Neuropsychopharmacology; 2003 Jul 10; 28(7):1317-27. PubMed ID: 12784121
    [Abstract] [Full Text] [Related]

  • 9. Three amino acids in the D2 dopamine receptor regulate selective ligand function and affinity.
    Cummings DF, Ericksen SS, Schetz JA.
    J Neurochem; 2009 Jul 10; 110(1):45-57. PubMed ID: 19486266
    [Abstract] [Full Text] [Related]

  • 10. Ring substituents on substituted benzamide ligands indirectly mediate interactions with position 7.39 of transmembrane helix 7 of the D4 dopamine receptor.
    Ericksen SS, Cummings DF, Teer ME, Amdani S, Schetz JA.
    J Pharmacol Exp Ther; 2012 Aug 10; 342(2):472-85. PubMed ID: 22588261
    [Abstract] [Full Text] [Related]

  • 11. Zinc modulates antagonist interactions with D2-like dopamine receptors through distinct molecular mechanisms.
    Schetz JA, Chu A, Sibley DR.
    J Pharmacol Exp Ther; 1999 May 10; 289(2):956-64. PubMed ID: 10215675
    [Abstract] [Full Text] [Related]

  • 12. Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior.
    Collins GT, Witkin JM, Newman AH, Svensson KA, Grundt P, Cao J, Woods JH.
    J Pharmacol Exp Ther; 2005 Jul 10; 314(1):310-9. PubMed ID: 15833897
    [Abstract] [Full Text] [Related]

  • 13. Regulation of dopamine D2 receptors by sodium and pH.
    Neve KA.
    Mol Pharmacol; 1991 Apr 10; 39(4):570-8. PubMed ID: 2017157
    [Abstract] [Full Text] [Related]

  • 14. Interactions of N-{[2-(4-phenyl-piperazin-1-yl)-ethyl]-phenyl}-2-aryl-2-yl-acetamides and 1-{[2-(4-phenyl-piperazin-1-yl)-ethyl]-phenyl}-3-aryl-2-yl-ureas with dopamine D2 and 5-hydroxytryptamine 5HT(1A) receptors.
    Sukalovic V, Ignjatovic D, Tovilovic G, Andric D, Shakib K, Kostic-Rajacic S, Soskic V.
    Bioorg Med Chem Lett; 2012 Jun 15; 22(12):3967-72. PubMed ID: 22607670
    [Abstract] [Full Text] [Related]

  • 15. The agonist activities of the putative antipsychotic agents, L-745,870 and U-101958 in HEK293 cells expressing the human dopamine D4.4 receptor.
    Gazi L, Bobirnac I, Danzeisen M, Schüpbach E, Bruinvels AT, Geisse S, Sommer B, Hoyer D, Tricklebank M, Schoeffter P.
    Br J Pharmacol; 1998 Jul 15; 124(5):889-96. PubMed ID: 9692773
    [Abstract] [Full Text] [Related]

  • 16. All-Atom Molecular Dynamics Investigations on the Interactions between D2 Subunit Dopamine Receptors and Three 11C-Labeled Radiopharmaceutical Ligands.
    Moldovean SN, Timaru DG, Chiş V.
    Int J Mol Sci; 2022 Feb 11; 23(4):. PubMed ID: 35216115
    [Abstract] [Full Text] [Related]

  • 17. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
    Glennon JC, Van Scharrenburg G, Ronken E, Hesselink MB, Reinders JH, Van Der Neut M, Long SK, Feenstra RW, McCreary AC.
    Synapse; 2006 Dec 15; 60(8):599-608. PubMed ID: 17001660
    [Abstract] [Full Text] [Related]

  • 18. S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride.
    Millan MJ, Newman-Tancredi A, Brocco M, Gobert A, Lejeune F, Audinot V, Rivet JM, Schreiber R, Dekeyne A, Spedding M, Nicolas JP, Peglion JL.
    J Pharmacol Exp Ther; 1998 Oct 15; 287(1):167-86. PubMed ID: 9765336
    [Abstract] [Full Text] [Related]

  • 19. Molecular basis for the binding of 2-aminotetralins to human dopamine D2A and D3 receptors.
    Malmberg A, Nordvall G, Johansson AM, Mohell N, Hacksell U.
    Mol Pharmacol; 1994 Aug 15; 46(2):299-312. PubMed ID: 8078492
    [Abstract] [Full Text] [Related]

  • 20. Synthesis and evaluation of fluorine-substituted 1H-pyrrolo[2,3-b]pyridine derivatives for dopamine D4 receptor imaging.
    Oh SJ, Lee KC, Lee SY, Ryu EK, Saji H, Choe YS, Chi DY, Kim SE, Lee J, Kim BT.
    Bioorg Med Chem; 2004 Nov 01; 12(21):5505-13. PubMed ID: 15465327
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.